How could the new cardiac data presented at the AHA Scientific Sessions affect Cleveland Clinic?
New cardiac data may prompt changes to guidelines used by Cleveland Clinic The presentation of 52-week extension data for BHB-1893, a cardiac myosin inhibitor, at the American Heart Association Scientific Sessions introduces new clinical evidence regarding hypertrophic cardiomyopathy. This new data could prompt the American Heart Association to review or update its medical guidelines. Since the clinical practice and research of Cleveland Clinic are informed and guided by guidelines published by the American Heart Association, any such update would necessitate changes in the clinic's protocols and research focus.
- Effect
- Mixed
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches Cleveland Clinic
-
Carlos del Rio presented research at the American Heart Association Scientific Sessions 2026. The presentations included 52-week extension results for BHB-1893 in obstructive hypertrophic cardiomyopathy and an oral abstract on the drug's ability to improve diastolic function in non-obstructive hypertrophic cardiomyopathy. The presentations were announced by Braveheart Bio, Inc. in October 2026.
The full event1independent outlet -
The American Heart Association publishes guidelines that inform and guide the clinical practice and research of Cleveland Clinic. New scientific data presented at its sessions can influence the revision or adoption of these official guidelines.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
nonprofit multispecialty academic medical center based in Cleveland, Ohio, United States
Everything about Cleveland Clinic
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Carlos del Rio presented 52-week extension data for BHB-1893 at the AHA Scientific Sessions 2026.manilatimes.net
- BHB-1893 is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) for hypertrophic cardiomyopathy (HCM).manilatimes.net
- The clinical practice and research of Cleveland Clinic are informed and guided by guidelines published by the American Heart Association.manilatimes.net
Why it matters
Hypertrophic cardiomyopathy (HCM) is a serious cardiovascular disease, and the development of next-generation therapies like BHB-1893 represents a significant advancement in treatment options. For academic medical centers like Cleveland Clinic, staying current with the latest clinical evidence is critical to providing optimal patient care and advancing medical research.
Cleveland Clinic, as a multispecialty academic medical center, relies heavily on established medical consensus and guidelines. The presentation of robust, long-term efficacy and safety data at a major forum like the AHA Scientific Sessions could shift the standard of care for HCM, requiring the clinic to adapt its protocols to incorporate the newest evidence.
What we don't know yet
- Will the American Heart Association formally adopt the data presented on BHB-1893?
- What specific changes, if any, would the AHA guidelines make regarding HCM treatment?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- manilatimes.netFriday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.